3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
26
Lymphoma, Mantle-Cell
18
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Waldenstrom Macroglobulinemia
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia, B-Cell
3
Pancreatic Neoplasms
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Ovarian Neoplasms
1
Neuritis
1
Neoplasm, Residual
1
Lymphoproliferative Disorders
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Hematologic Neoplasms
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Anemia, Hemolytic, Autoimmune
1
Interventions
Carboplatin
361
Pemetrexed
276
Cisplatin
230
Paclitaxel
213
Docetaxel
205
Gemcitabine
160
Erlotinib Hydrochloride
150
Bevacizumab
132
pembrolizumab
129
Radiotherapy
114
Nivolumab
88
durvalumab
84
Drug Therapy
84
osimertinib
82
atezolizumab
58
Vinorelbine
53
Gefitinib
53
Radiosurgery
50
Cetuximab
39
Taxes
37
130-nm albumin-bound paclitaxel
36
Ipilimumab
34
anlotinib
33
Surgical Procedures, Operative
33
Magnetic Resonance Spectroscopy
33
Etoposide
30
Albumin-Bound Paclitaxel
29
tislelizumab
27
icotinib
27
aflutinib
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Non-Small-Cell Lung
×
acalabrutinib
×
Clear all
NCT02448303
2019-09-12
KEYNOTE166
Acerta Pharma BV
Phase 2
Completed
74 enrolled
10 charts